MYC 蛋白家族的成员是癌症药物发现的主要目标，但阻止 MYC 驱动的癌症的药物开发尚未成功。取得成功的方法可能包括开发针对多个节点的 MYC 的联合疗法或双效药物。此类治疗具有相加或协同活性的可能性，有可能减少副作用和耐药性的出现。在这篇综述中，我们研究了与 MYC 相关的重要靶标，并重点介绍了那些以组合和/或双靶标方法为目标的靶标。最后，我们从药物开发的角度探讨了组合和双靶点方法的挑战。版权所有 © 2024 Elsevier Ltd。保留所有权利。

Members of the MYC family of proteins are a major target for cancer drug discovery, but the development of drugs that block MYC-driven cancers has not yet been successful. Approaches to achieve success may include the development of combination therapies or dual-acting drugs that target MYC at multiple nodes. Such treatments hold the possibility of additive or synergistic activity, potentially reducing side effect profiles and the emergence of resistance. In this review, we examine the prominent MYC-related targets and highlight those that have been targeted in combination and/or dual-target approaches. Finally, we explore the challenges of combination and dual-target approaches from a drug development perspective.Copyright © 2024 Elsevier Ltd. All rights reserved.